In solid-phase peptide synthesis campaigns for injectable peptide active pharmaceutical ingredients, Fmoc-L-Asparagine is handled as an N-α-Fmoc-protected L-asparagine building block with a free side-chain primary amide. The material is dissolved in DMF or NMP at 0.05–0.20 M, activated in situ with HATU/DIPEA or HBTU/HOBt/DIPEA, and coupled to deprotected peptidyl resin at a molar excess of 2.5–4.0 eq relative to free amino sites. Production campaigns on Rink amide AM resin at substitution levels of 0.25–0.40 mmol/g typically require double coupling of Fmoc-L-Asn when the following residue is sterically hindered; coupling is executed at 25–35°C for 45–90 min, with nitrogen-bubbled mixing in recirculating-loop solid-phase reactors. Fmoc removal proceeds with 20% piperidine in DMF for 10–20 min at ambient temperature. Under ICH Q7 and ICH Q3C, residual solvent limits for DMF and piperidine in the isolated peptide acetic acid salt are controlled using USP <467>; release testing for purity uses HPLC per USP <621>. The free side-chain amide is sensitive to prolonged carbodiimide-only activation: DIC without HOBt can dehydrate the asparagine side chain to β-cyanoalanine at ambient temperature over 2 h, so protocol design avoids DIC activation when no racemization-suppressing additive is present. Acidic cleavage with TFA/TIS/water 95:2.5:2.5 v/v/v for 2–3 h removes side-chain protecting groups from other residues while keeping Fmoc-L-Asn-derived Asn units intact, but extended cleavage above 25°C or beyond 3 h can hydrolyze the primary amide to a carboxylic acid. Terminal product classes include linear therapeutic peptides, N-terminal acetylated or amidated drug candidates, and freeze-dried acetate or hydrochloride salts for parenteral formulation.

What Limits Coupling Efficiency of Fmoc-L-Asparagine in Microwave-Assisted Solid-Phase Synthesis?

Microwave-assisted SPPS raises the coupling temperature and shortens the period during which the unprotected Asn side chain can undergo carbodiimide-mediated dehydration. Fmoc-L-Asparagine is coupled at 75°C for 5–10 min using 2.0–3.0 eq of HATU and 4.0–6.0 eq of DIPEA in NMP, with the molar excess relative to resin free amines held at the lower end because the side-chain primary amide competes weakly with solvent nucleophiles under microwave dielectric heating. Deprotection uses 20% piperidine with microwave pulses of 3–5 min at 75°C. Closed-architecture microwave peptide synthesizers with fiber-optic temperature control and inline UV monitoring at 280 nm are used to follow Fmoc removal; instrument electrical safety is qualified under IEC 61010-1:2010, electronic batch records are maintained under FDA 21 CFR Part 11, and in-process analytical methods are validated under ICH Q2(R1). The critical process threshold is resin substitution: at substitutions above 0.5 mmol/g, microwave conditions can intensify interchain aggregation when Asn-containing sequences include hydrophobic residues, and coupling efficiency drops unless pseudoproline dipeptide building blocks are inserted at suitable sites. Cleavage is performed with TFA/TIS/water 95:2.5:2.5 v/v/v, followed by precipitation in methyl tert-butyl ether, preparative HPLC purification, and lyophilization. Terminal product types include long-chain peptides, difficult-sequence peptides, and Asn-containing fragments for preclinical pharmacology. Published data for systematic comparisons of Fmoc-L-Asn coupling efficiency across different microwave reactor geometries is limited, but the operational risk of side-chain dehydration is consistently reported for DIC-only activation at elevated temperature.

In preclinical contract peptide synthesis, Fmoc-L-Asparagine is weighed and handled in low-humidity laminar flow stations because ambient moisture above 60% RH increases hydration of the free side-chain amide and shifts the effective molar ratio during activation. The compound is dissolved in DMF at 0.2 M and activated with DIC/HOBt at a 1:1:1 molar ratio before addition to Wang or 2-chlorotrityl chloride resin; the molar excess relative to resin substitution of 0.4–0.8 mmol/g is maintained at 2.0–3.0 eq. Non-GMP operations follow ISO 9001:2015 for batch traceability, REACH registration for import, and residual solvent testing under USP <467>. Automated bench-scale synthesizers with UV monitoring at 280 nm execute Fmoc deprotection with 20% piperidine/DMF; cleavage from 2-chlorotrityl resin uses 1% TFA in DCM, while Wang-resin peptides are cleaved with TFA/TIS/EDT 94:2:2:2 v/v/v. Crude peptide is precipitated in cold diethyl ether, purified by preparative RP-HPLC at 220 nm, and characterized by ESI-LC-MS. Terminal product types include linear peptides for antibody production, enzyme substrates, structure-activity relationship libraries, and peptide standards for assay development. A specified moisture content below 0.5% in the Fmoc-L-Asparagine lot is a practical prerequisite for reproducible coupling in batches above 50 g; otherwise lot-to-lot variation in water content alters in situ active ester concentration and causes incomplete coupling.

Peptide Vaccine Epitope Synthesis and Long-Chain Residue Coupling

Asn-containing synthetic peptide epitopes are assembled on Rink amide AM resin or MBHA resin using Fmoc-L-Asparagine at 4.0 eq excess with HATU/DIPEA activation in DMF. The additional stoichiometry compensates for the steric demand of Asn side-chain hydration and permits single coupling in epitopes of 15–25 residues; for sequences longer than 30 residues, double coupling with fresh activation is required. Compliance for research-grade vaccine-related peptide intermediates follows ISO 9001:2015, while batches intended for clinical trial material are manufactured under ICH Q7; residual solvent limits are controlled under USP <467>, and quality risk management follows ICH Q9. After cleavage with TFA/TIS/thioanisole 90:5:5 v/v/v, the peptide is purified by preparative HPLC and conjugated to carrier proteins such as keyhole limpet hemocyanin or tetanus toxoid through maleimide-thiol or carbodiimide-mediated linkages. Conjugation pH is maintained between 6.5 and 7.0 to avoid succinimide formation from neighboring Asp residues; Asn side chains remain unmodified. Terminal product types include peptide immunogens, neoepitope vaccine candidates, HLA-restricted T-cell epitope libraries, and peptide-carrier conjugates for immuno-oncology research. Published data for Fmoc-L-Asn-derived epitope coupling at very high resin loadings above 1.0 mmol/g is limited, and such high loadings are avoided because interchain proximity promotes aggregation and lowers amide coupling yield.

When Fmoc-L-Asparagine Is Positioned at a Beta-Turn of a Macrocyclic Peptide

When a macrocyclic peptide sequence places the Asn residue at or adjacent to a beta-turn, Fmoc-L-Asparagine is incorporated at 2.5 eq with HATU/DIPEA at 0–5°C to minimize epimerization during slow-turn coupling. The linear precursor is assembled on 2-chlorotrityl chloride resin at 0.3–0.6 mmol/g; after cleavage with 1% TFA in DCM, side-chain protection is retained for solution-phase cyclization. Cyclization is performed under high dilution at 1 mM peptide concentration in DMF/THF using PyBOP/DIPEA at 1.2 eq for 24 h at 4°C. The unprotected primary amide of Asn remains stable under these conditions, but extended exposure to basic pH above 8.0 beyond 24 h can facilitate hydrolysis of any isomerized Asp ester and complicate purification; mass-directed preparative RP-HPLC is used to resolve the target cyclic peptide from linear precursors. Compliance for this development segment is governed by ICH Q11 for starting material identity, ICH Q3C for solvent carryover, and USP <621> for chromatographic purity. Terminal product types include constrained macrocyclic peptide drug candidates, integrin-binding cyclic RGD variants, and beta-turn peptidomimetics for screening.

Cosmetic Peptide Active Manufacture Under EC 1223/2009

Fmoc-L-Asparagine is used in solid-phase peptide synthesis of cosmetic active ingredients that incorporate Asn residues at internal or terminal positions. Coupling is executed at 2.0–3.0 eq on Rink amide resin using HBTU/HOBt/DIPEA in DMF at 25°C for 45–60 min; Fmoc removal with 20% piperidine/DMF is followed by UV monitoring at 280 nm to confirm deprotection completion. Manufacturing of cosmetic peptide powders is controlled under ISO 22716:2007 and EC 1223/2009 Article 10, with the final product evaluated by a qualified safety assessor before use in skin care formulations. Cleavage with TFA/TIS/water 95:2.5:2.5 v/v/v is followed by preparative HPLC purification to ≥95% purity, counter-ion exchange from trifluoroacetate to acetate, and lyophilization. Residual TFA is commonly specified below 0.1% in cosmetic peptide active powders, and residual DMF is controlled under USP <467>. Terminal product types include anti-wrinkle peptide powders, skin-repair peptide concentrates, and encapsulated peptide systems for serum or emulsion delivery. The operational boundary is acid-lability of the Asn side chain: TFA cleavage extended beyond 3 h at temperatures above 25°C increases the proportion of Asn-to-Asp hydrolysis product and must be monitored by HPLC.

Peptide-drug conjugate and diagnostic peptide manufacturing uses Fmoc-L-Asparagine when a targeting peptide chain requires Asn residues for receptor affinity or solubility. The Asn building block is coupled at 2.0–3.0 eq with HATU/DIPEA on Rink amide resin at 0.25–0.50 mmol/g, followed by standard Fmoc deprotection and cleavage with TFA/TIS/water 95:2.5:2.5 v/v/v. For conjugates, orthogonally protected Lys or Cys is inserted during SPPS, then the purified peptide is conjugated to maleimide-functionalized payloads or DOTA-type chelators under pH 6.5–7.0; Asn side chains are not involved in conjugation but must remain intact during deprotection of side-chain protecting groups. Compliance for conjugated peptide APIs follows ICH Q7 and ICH Q3C; if a diagnostic radio-peptide is produced, manufacturing records align with ISO 13485:2016 and applicable radiopharmaceutical regulations. Process equipment includes automated peptide synthesizers, preparative HPLC, and for radiometal labeling, shielded hot cells with TLC and HPLC release. Terminal product types include peptide-drug conjugates, radiolabeled diagnostic peptides, and fluorescent or biotinylated peptide probes for molecular imaging. Published data for Asn-specific stability in these conjugated peptide platforms is limited; therefore, each new sequence requires a forced-degradation study under acidic cleavage and radiolabeling conditions before lot release.